Bone Marrow and Peripheral Blood Cell Donors and Donor Registries

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 544-558

  Confer, Dennis L ^a,b   Miller, John P ^c   Chell, Jeffrey W ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c NONE

Author keywords

Bone marrow and peripheral blood cell donors and donor registries; Donation procedures; Ethical and psychosocial issues; German National Bone Marrow Donor Registry (ZKRD), w; Growth factor mobilized bone marrow; Peripheral blood HCs; Unrelated donors and unrelated donor registries; World Marrow Donor Association (WMDA)

Indexed keywords

EID: 84871880474     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch38     Document Type: Chapter

References (185)

1. Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation. 1. N Engl J Med 1975; 292: 832-43.
2. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. 2. N Engl J Med 1975; 292: 895-902.
3. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Ann Intern Med 1992; 116: 505-12.
4. Armitage J. Bone marrow transplantation. N Engl J Med 1994; 330: 827-38.
5. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-87.
6. Eapen M, Horowitz MM, Klein JP et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-80.
7. Hansen JA, Clift RA, Thomas ED et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980; 303: 565-7.
8. Horowitz SD, Bach FH, Groshong T, Hong R, Yunis EJ. Treatment of severe combined immunodeficiency with bone-marrow from an unrelated, mixed-leucocyte-culture-non-reactive donor. Lancet 1975; 2: 431-3.
9. Speck B, Zwaan FE, van Rood JJ, Eernisse JG. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HLA-identical unrelated donor. Transplantation 1973; 16: 24-8.
10. Goldman J. Bone marrow transplants using volunteer donors -recommendations and requirements for a standardized practice throughout the world. Bone Marrow Transplant 1992; 10: 287-91.
11. Goldman JM. A special report: bone marrow transplants using volunteer donors -recommendations and requirements for a standardized practice throughout the world -1994 update. Blood 1994; 84: 2833-9.
12. Goldman JM, Cleaver S, Warren P. World Marrow Donor Association: a progress report. Bone Marrow Transplant 1994; 13: 689-91.
13. Gahrton G, van Rood JJ, Oudshoorn M, World Marrow Donor Association. The World Marrow Donor Association (WMDA): its goals and activities. Bone Marrow Transplant 2003; 32: 121-4.
14. Hurley CK, Raffoux C, World Marrow Donor Association. World Marrow Donor Association: international standards for unrelated hematopoietic stem cell donor registries. Bone Marrow Transplant 2004; 34: 103-10.
15. World Marrow Donor Association Donor Registries Working Group. Annual Report 2006, 10th edn. Leiden: World Marrow Donor Association; 2007.
16. McCullough J, Perkins HA, Hansen J. The National Marrow Donor Program with emphasis on the early years. Transfusion 2006; 46: 1248-55.
17. American Association of Blood Banks. Standards for Cellular Therapy Product Services, 2nd edn. Bethesda: American Association of Blood Banks; 2007.
18. Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee -ISCT and EBMT. FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration, 3rd edn. Omaha: Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee -ISCT and EBMT; 2006.
19. National Marrow Donor Program. National Marrow Donor Program Standards, 19th edn. Minneapolis: National Marrow Donor Program; 2004.
20. Food and Drug Administration. Proposed Approach to Regulation of Cellular and Tissuebased Products. Washington, DC: US Department of Health and Human Services; 1997.
21. US National Archives and Records Administration. 21 CFR, Part 1271. Washington, DC: GPO; 2004.
22. Food and Drug Administration. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue- Based Products (HCT/Ps). Washington, DC: US Department of Health and Human Services; 2007.
23. US National Archives and Records Administration. 21 CFR, Part 1271, Subpart C -Donor Eligibility. Washington, DC: GPO; 2004.
24. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999; 93: 1127-36.
25. Vance EA, Soiffer RJ, McDonald GB et al. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation 1996; 62: 1358-60.
26. Chen P-M, Fan S, Liu C-J et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49: 708-13.
27. Ilan Y, Nagler A, Adler R et al. Adoptive transfer of immunity to hepatitis B virus after T celldepleted allogeneic bone marrow transplantation. Hepatology 1993; 18: 246-52.
28. Ilan Y, Nagler A, Adler R et al. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993; 104: 1818-21.
29. Ilan Y, Nagler A, Shouval D et al. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol 1994; 97: 299-302.
30. Lau GKK, Liang R, Lee CK et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody- positive. J Infect Dis 1998; 178: 1585-91.
31. Lau GKK, Lie AKW, Kwong YL et al. A casecontrolled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000; 96: 452-8.
32. Locasciulli A, Alberti A, Bandini G et al. Allogeneic bone marrow transplantation from HBsAg+ donors: A multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995; 86: 3236-40.
33. Kollman C, Howe CWS, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-51.
34. Lee SJ, Klein J, Haagenson M et al. High resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-83.
35. Grob JP, Grundy JE, Prentice HG et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774-6.
36. Ljungman P, Brand R, Einsele H et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255-60.
37. Lutz E, Ward KN, Szydlo R, Goldman JM. Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status. J Med Virol 1996; 49: 61-5.
38. Peters SO, Stockschlader M, Zeller W et al. Monoclonal gammopathy of unknown signifi- cance in a bone marrow donor. Ann Hematol 1993; 66: 93-5.
39. Centis F, Delfini C, Agostinelli F et al. Soluble transferrin receptor following bone marrow transplantation from donors heterozygous for beta thalassemia. Haematologica 1994; 79: 448-51.
40. Peltier JY, Girault D, Debre M et al. Donor for BMT with haemoglobin H disease. Bone Marrow Transplant 1993; 12: 81-4.
41. Barquinero J, Witherspoon R, Sanders J et al. Allogeneic marrow grafts from donors with congenital chromosomal abnormalities in marrow cells. Br J Haematol 1995; 90: 595-601.
42. DeFour Jones M, Petrikovsky BM, Sahdev I, Prisco M. Continuous fetal heart rate monitoring during bone marrow harvesting in pregnancy. Am J Perinatol 1995; 12: 243-4.
43. Calder C, Hays SR, Manes B et al. Successful bone marrow harvest during pregnancy. Bone Marrow Transplant 2005; 35: 631-2.
44. Cavallaro AM, Lilleby K, Majolino I et al. Three to six year follow-up of normal donors who receive recombinant human granulocyte colonystimulating factor. Bone Marrow Transplant 2000; 25: 85-9.
45. Switzer GE, Dew MA, Butterworth VA, Simmons RG, Schimmel M. Understanding donors' motivations: a study of unrelated bone marrow donors. Soc Sci Med 1997; 45: 137-47.
46. Chang G, McGarigle C, Spitzer TR et al. A comparison of related and unrelated marrow donors. Psychosom Med 1998; 60: 163-7.
47. Chang G, McGarigle C, Koby D, Antin JH. Symptoms of pain and depression in related marrow donors: changes after transplant. Psychosomatics 2003; 44: 59-64.
48. Davies S. Bone marrow transplant raises issues of privacy. Br Med J 1997; 314: 1356.
49. Warwick R. Anonymity for unrelated bone marrow donors should remain [Letter]. BMJ 1997; 315: 548-9.
50. Stroncek D, Strand R, Scott E et al. Attitudes and physical condition of unrelated bone marrow donors immediately after donation. Transfusion 1989; 29: 317-22.
51. US National Archives and Records Administration. 45 CFR, Part 46. Washington, DC: GPO; 2005.
52. US National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: GPO; 1978.
53. National Marrow Donor Program. Now That You Are a Match. Minneapolis: National Marrow Donor Program; 2007.
54. Clayton EW, Steinberg KK, Khoury MJ et al. Consensus statement. Informed consent for genetic research on stored tissue samples. JAMA 1995; 274: 1786-92.
55. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970; 36: 507-15.
56. Buckner CD, Clift RA, Sanders JE et al. Marrow harvesting from normal donors. Blood 1984; 64: 630-4.
57. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemia burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226-35.
58. Mijovic A, Britten C, Regan F, Harrison J. Preoperative autologous blood donation for bone marrow harvests: are we wasting donors' time and blood? Transfus Med 2006; 16: 57-62.
59. Parkkali T, Juvonen E, Volin L, Partanen J, Ruutu T. Collection of autologous blood for bone marrow donation: how useful is it? Bone Marrow Transplant 2005; 35: 1035-9.
60. Stroncek D, McCullough J. Policies and procedures for the establishment of an allogeneic blood stem cell collection programme. Transfus Med 1997; 7: 77-87.
61. Ings SJ, Balsa C, Leverett D et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-25.
62. Martino M, Morabito F, Callea I et al. Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. Transfus Med 2005; 15: 323-8.
63. Flomenberg N, Devine SM, Dipersio JF et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74.
64. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39: 577-88.
65. de Fabritiis P, Paola Iori A, Mengarelli A et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion 2001; 41: 190-5.
66. Kobbe G, Soehngen D, Heyll A et al. Large volume leukapheresis maximizes the progenitor cell yield for allogeneic peripheral blood progenitor donation. J Hematother 1997; 6: 125-31.
67. Adorno G, Del Proposto G, Palombi F et al. Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators. Transfus Apher Sci 2004; 30: 131-6.
68. Ikeda K, Ohto H, Nemoto K et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial. Transfusion 2003; 43: 814-19.
69. Stroncek D, Clay M, Smith J et al. Composition of peripheral blood progenitor cell components collected from healthy donors. Transfusion 1997; 37: 411-17.
70. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1997; 96: 415-17.
71. Körbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-8.
72. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-65.
73. Majolina I, Cavallaro A, Bacigalupo A et al. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Marrow Transplantation Group (GITMO). Haematologica 1997; 82: 47-52.
74. Miflin G, Charley C, Stainer C et al. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 1996; 95: 345-8.
75. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocytecolony- stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590-5.
76. Hill H, Chapman C, Jackson T, Sullivan K. Assessment and management of donor pain following marrow harvest for allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 157-61.
77. Stroncek DF, Holland PV, Bartch G et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood 1993; 81: 1940-6.
78. Burmeister MA, Standl T, Brauer P et al. Safety and efficacy of spinal vs general anaesthesia in bone marrow harvesting. Bone Marrow Transplant 1998; 21: 1145-8.
79. Buckner CD, Petersen FB, Bolonski BA. Bone marrow donors. In: Forman SJ, Blume KG, Thomas ED, editors. Bone Marrow Transplantation. Boston: Blackwell Scientific Publications; 1994. pp. 259-69.
80. Foldes J, Naparstek E, Statter M, Menczel J, Bab I. Osteogenic response to marrow aspiration: increased serum osteocalcin and alkaline phosphatase in human bone marrow donors. J Bone Miner Res 1989; 4: 643-6.
81. Fondriest JE, Pitt MJ, Williams WH, Dalton WS. Radiologic abnormalities at the harvest site in patients undergoing bone marrow transplantation. Am J Roentgenol 1992; 159: 226-7.
82. Kroschinsky F, Kittner T, Mauersberger S et al. Pelvic magnetic resonance imaging after bone marrow harvest -a retrospective study in 50 unrelated marrow donors. Bone Marrow Transplant 2005; 35: 667-73.
83. Bortin MM, Buckner CD. Major complications of marrow harvesting for transplantation. Exp Hematol 1983; 11: 916-21.
84. Hosoya N, Miyagawa K, Mimura T et al. Malignant hyperthermia induced by general anesthesia for bone marrow harvesting. Bone Marrow Transplant 1996; 19: 509-11.
85. Riley D, Evans TG. Osteomyelitis complicating bone marrow harvest [Letter]. Clin Infect Dis 1992; 14: 980-1.
86. Drake P. Hemorrhage after bone marrow harvest: a case presentation. Clin J Oncol Nurs 2000; 4: 29-31.
87. Klumpp TR, Mangan KF, MacDonald JS, Mesgarzadeh M. Fracture of the ilium: an unusual complication of bone marrow harvesting. Bone Marrow Transplant 1992; 9: 503-4.
88. Sanders J, Buckner CD, Bensinger WI et al. Experience with marrow harvesting from donors less than two years of age. Bone Marrow Transplant 1987; 2: 45-50.
89. Kletzel M, Olezewski M, Danner-Koptik K, Coyne K, Haut PR. Red cell salvage and reinfusion in pediatric bone marrow donors. Bone Marrow Transplant 1999; 24: 385-8.
90. Akiyama H, Tanikawa S, Takamoto S et al. Recombinant human erythropoietin (rhEPO) administration to marrow donors. Bone Marrow Transplantation (BMT) Team. Int J Hematol 1995; 62: 145-9.
91. York A, Clift RA, Sanders JE, Buckner CD. Recombinant human erythropoietin (rh-Epo) administration to normal marrow donors. Bone Marrow Transplant 1992; 10: 415-17.
92. Baselga J, Reich L, Doherty M, Gulati S. Fat embolism syndrome following bone marrow harvesting. Bone Marrow Transplant 1991; 7: 485-6.
93. Wolf HH, Heyll A, Hesterberg R et al. Mechanical ileus following bone marrow harvesting: an unusual complication [Letter]. Bone Marrow Transplant 1994; 14: 179-80.
94. Agura ED. Seizure in a normal marrow donor: Addison's disease unmasked. Bone Marrow Transplant 1994; 13: 215-16.
95. Sturfelt G, Lenhoff S, Sallerfors B et al. Transplantation with allogeneic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor. Ann Rheum Dis 1996; 55: 638-41.
96. Anderlini P, Rizzo JD, Nugent ML et al. Peripheral blood stem cell donation: an analysis from the international bone marrow transplant registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689-92.
97. Adler BK, Salzman DE, Carabasi MH et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001; 97: 3313-4.
98. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors [Editorial]. Blood 1997; 90: 903-8.
99. Blazar BR, Lasky LC, Perentesis JP et al. Successful donor cell engraftment in a recipient of bone marrow from a cadaveric donor. Blood 1986; 67: 1655-60. Bone Marrow and Peripheral Blood Cell Donors and Donor Registries 557.
100. Martin J. Offer to give all chilling prophecy before surgery. South Bend Tribune, September 1, 1998.
101. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97: 2541-8.
102. Anderlini P, Donato M, Chan K-W et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999; 39: 555-60.
103. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-8.
104. Dreger P, Haferlach T, Eckstein V et al. G-CSFmobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-13.
105. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-45.
106. Majolino I, Cavallaro AM, Bacigalupo A et al. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). Haematologica 1997; 82: 47-52.
107. Murata M, Harada M, Kato S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065-71.
108. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-72.
109. Stroncek DF, Clay ME, Petzoldt ML et al. Treatment of normal individuals with granulocytecolony- stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 601-10.
110. Froberg MK, Garg UC, Stroncek DF et al. Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colonystimulating factor for peripheral blood stem and progenitor cell collection. Transfusion 1999; 39: 410-14.
111. Anderlini P, Prezpiorka D, Seong D, Champlin R, Körbling M. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996; 94: 155-8.
112. Bensinger WI, Buckner CD, Rowley S, Storb R, Appelbaum FR. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant 1996; 17: S19-21.
113. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colonystimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82.
114. Murata M, Kanie T, Hamaguchi M et al. Unrelated bone marrow transplantation from the National Marrow Donor Program. Int J Hematol 1997; 66: 239-43.
115. Körbling M, Chan KW, Anderlini P et al. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant 1996; 18: 885-90.
116. Majolino I, Buscemi F, Scime R et al. Treatment of normal donors with rhG-CSF 16 micrograms/ kg for mobilization of peripheral blood stem cells and their apheretic collection for allogeneic transplantation. Haematologica 1995; 80: 219-26.
117. Martinez C, Urbano-Ispizua A, Rozman C et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996; 72: 269-72.
118. Stroncek DF, Clay ME, Smith J et al. Comparison of two blood cell separators in collecting peripheral blood stem cell components. Transfus Med 1997; 7: 95-9.
119. Körbling M, Anderlini P, Durett A et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+Thy- 1dim CD38- progenitor cells and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant 1996; 18: 1073-9.
120. Wei A, Grigg A. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/B+ thalassemia. Blood 2001; 97: 3998-9.
121. Kang E, Areman E, David-Ocampo V et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99: 850-5.
122. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45-9.
123. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.
124. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J. Splenic rupture after granulocytecolony- stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260-1.
125. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004; 26: 761-3.
126. Kroger N, Renges H, Sonnenberg S et al. Stem cell mobilisation with 16 microg/kg vs 10 microg/ kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002; 29: 727-30.
127. Platzbecker U, Prange-Krex G, Bornhäuser M et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184-9.
128. Stroncek D, Shawker T, Follmann D, Leitman S. G CSF induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609-13.
129. Stroncek DF, Dittmar K, Shawker T, Heatherman A, Leitman SF. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004; 2: 25.
130. De Vries EGE, Willemse PHB, Biesma B et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy [Letter]. Lancet 1991; 338: 517-18.
131. Hoekman K, von Blomberg-van der Flier BME, Wagstaff J, Drexhage HA, Pinedo HM. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541-2.
132. Huhn RD, Yurkow EJ, Tushinski R et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colonystimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 1996; 24: 839-47.
133. Parkkali T, Volin L, Siren MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant 1996; 17: 433-4.
134. Storek J, Glaspy JA, Grody WW, Susi E, Slater ED. Adult-onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis. Am J Hematol 1993; 43: 139-43.
135. Esmaeli B, Ahmadi MA, Kim S et al. Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor. Cornea 2002; 21: 621-2.
136. Bennett CL, Evens AM, Andritsos LA et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.[see comment]. Br J Haematol 2006; 135: 642-50.
137. Makita K, Ohta K, Mugitani A et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661-5.
138. Pottern LM, Linet M, Blair A et al. Familial cancers associated with subtypes of leukemia and non-Hodgkins-lymphoma. Leuk Res 1991; 15: 305-14.
139. Rauscher GH, Sandler DP, Poole C et al. Family history of cancer and incidence of acute leukemia in adults. Am J Epidemiol 2002; 156: 517-26.
140. Shpilberg O, Modan M, Modan B et al. Familial aggregation of hematological neoplasms -a controlled-study. Br J Haematol 1994; 87: 75-80.
141. Hernandez JM, Castilla C, Gutierrez NC et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088-91.
142. Kaplinsky C, Trakhtenbrot L, Hardan I et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31-4.
143. Nagler A, Ilan Y, Adler R et al. Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination. Bone Marrow Transplant 1995; 15: 475-8.
144. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003; 73: 33-6.
145. Sakamaki S, Matsunaga T, Hirayama Y, Kuya T, Niitsu Y. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432-3.
146. Stroncek D, Clay M, Herr G et al. Blood counts in healthy donors 1 year after the collection of granulocyte-colony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997; 37: 304-8.
147. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002; 30: 661-3.
148. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77-8.
149. Switzer GE, Goycoolea JM, Dew MA, Graeff EC, Hegland J. Donating stimulated peripheral blood stem cells vs bone marrow: do donors experience the procedures differently? Bone Marrow Transplant 2001; 27: 917-23.
150. Fortanier C, Kuentz M, Sutton L et al. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: results of a randomised study. Bone Marrow Transplant 2002; 29: 145-9.
151. Kennedy GA, Morton J, Western R et al. Impact of stem cell donation modality on normal donor quality of life: a prospective randomized study. Bone Marrow Transplant 2003; 31: 1033-5.
152. Bredeson C, Leger C, Couban S et al. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405-14.
153. Heldal D, Brinch L, Tjonnfjord G et al. Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant 2002; 29: 479-86.
154. Chan KW, Gajewski JL, Supkis D, Jr. et al. Use of minors as bone marrow donors: current attitude and management. A survey of 56 pediatric transplantation centers. J Pediatr 1996; 128: 644-8.
155. Chan KW, Stanley CE, Wadsworth LD. Bone marrow collection from a 9.4-kg donor avoiding allogeneic blood transfusion [Letter]. Transfusion 1987; 27: 441-2.
156. Urban C, Weber G, Slavc I, Kerbl R. Anesthetic management of marrow harvesting from a 7- week-old premature baby. Bone Marrow Transplant 1990; 6: 443-4.
157. de la Rubia J, Diaz M, Verdeguer A et al. Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion 2001; 41: 201-5.
158. Pulsipher MA, Levine JE, Hayashi RJ et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 2005; 35: 361-7.
159. Kent G. Volunteering children for bone marrow donation. Studies show large discrepancies between views of surrogate decision makers and patients [Letter]. BMJ 1996; 313: 49-50.
160. Kinrade LC. Preparation of sibling donor for bone marrow transplant harvest procedure. Cancer Nurs 1987; 10: 77-81.
161. Heiney SP, Bryant LH, Godder K, Michaels J. Preparing children to be bone marrow donors. Oncol Nurs Forum Online 2002; 29: 1485-9.
162. MacLeod KD, Whitsett SF, Mash EJ, Pelletier W. Pediatric sibling donors of successful and unsuccessful hematopoietic stem cell transplants (HSCT): a qualitative study of their psychosocial experience. J Pediatr Psychol 2003; 28: 223-30.
163. Parmar G, Wu JW, Chan KW. Bone marrow donation in childhood: one donor's perspective. Psycho-Oncology 2003; 12: 91-4.
164. Anderson-Shaw L, Orfali K. Child-to-parent bone marrow donation for treatment of sickle cell disease. J Clin Ethics 2006; 17: 53-61.
165. Opel DJ, Diekema DS. The case of A.R.: the ethics of sibling donor bone marrow transplantation revisited [see comment]. J Clin Ethics 2006; 17: 207-19.
166. Pentz R. Duty and altruism: alternative analyses of the ethics of sibling bone marrow donation [Comment]. J Clin Ethics 2006; 17: 227-30.
167. Ross LF, Glannon W. A compounding of errors: the case of bone marrow donation between nonintimate siblings [Comment]. J Clin Ethics 2006; 17: 220-6.
168. Browett P, Palmer S. Altruism by proxy: volunteering children for bone marrow donation. Legal barriers might have catastrophic effects. BMJ 1996; 312: 242-3.
169. Month S. Altruism by proxy: volunteering children for bone marrow donation. Preventing children from donation may not be in their interests. Br Med J 1996; 312: 240-1.
170. Savulescu J. Altruism by proxy: volunteering children for bone marrow donation. Substantial harm but substantial benefit. Br Med J 1996; 312: 241-2.
171. US National Archives and Records Administration. 45 CFR, Part 46.408(a). Washington, DC: GPO; 2005.
172. Washington State Legislature. Bone marrow donation. Revised Code of Washington 2000; 70.54.305.
173. Associated Press. Young would-be marrow donor to be tested after all. Seattle Times, August 11, 1999.
174. Akiyama H, Hara M, Hino M et al. Second donation of bone marrow: results from the Japan Marrow Donor Program (JMDP). Bone Marrow Transplant 2006; 37: 795-6.
175. Stroncek DF, McGlave P, Ramsay N, McCullough J. Effects on donors of second bone marrow collections. Transfusion 1991; 31: 819-22.
176. de la Rubia J, Arbona C, Del Canizo C et al. Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields. J Hematother Stem Cell Res 2002; 11: 705-9.
177. Platzbecker U, Bornhauser M, Zimmer K et al. Second donation of granulocyte-colony-stimulating factor-mobilized peripheral blood progenitor cells: risk factors associated with a low yield of CD34+ cells. Transfusion 2005; 45: 11-15.
178. Porter D, Collins R, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214-21.
179. Couban S, Messner HA, Andreou P et al. Bone marrow mobilized with granulocyte colonystimulating factor in related allogeneic transplant recipients: a study of 29 patients. Biol Blood Marrow Transplant 2000; 6: 422-7.
180. Isola L, Scigliano E, Fruchtman S. Long-term follow-up after allogeneic granulocyte colonystimulating factor-primed bone marrow transplantation. Biol Blood Marrow Transplant 2000; 6: 428-33.
181. Ji S-Q, Chen H-R, Wang H-X et al. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colonystimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 261-7.
182. Serody JS, Sparks SD, Lin Y et al. Comparison of granulocyte colony-stimulating factor (GCSF)- mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434-40.
183. Machida U, Tojo A, Takahashi S et al. The effect of granulocyte colony-stimulating factor administration in healthy donors bone marrow harvesting. Br J Haematol 2000; 108: 747-53.
184. Morton J, Hutchins C, Durrant S. Granulocytecolony- stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graftversus- host disease and comparable engraftment of G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186-91.
185. Donato M, Champlin R. Granulocyte colonystimulating factor-primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 419-21.